Last reviewed · How we verify
MK-8998
At a glance
| Generic name | MK-8998 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease (PHASE2)
- A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-8998 CI brief — competitive landscape report
- MK-8998 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI